Arcutis Biotherapeutics Stock Today
| ARQT Stock | USD 12.68 1.07 7.78% |
Performance13 of 100
| Odds Of DistressOver 51
|
Arcutis Biotherapeutics is selling for under 12.68 as of the 19th of January 2025; that is 7.78 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 12.61. Arcutis Biotherapeutics has 51 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 30th of January 2023 and ending today, the 19th of January 2025. Click here to learn more.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 117.05 M outstanding shares of which 20.97 M shares are presently shorted by private and institutional investors with about 9.95 trading days to cover. More on Arcutis Biotherapeutics
Moving together with Arcutis Stock
Moving against Arcutis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Arcutis Stock Highlights
| CEO President | Todd MA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Arcutis Biotherapeutics (ARQT) is traded on NASDAQ Exchange in USA. It is located in 3027 Townsgate Road, Westlake Village, CA, United States, 91361 and employs 296 people. Arcutis Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.48 B. Arcutis Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 117.05 M outstanding shares of which 20.97 M shares are presently shorted by private and institutional investors with about 9.95 trading days to cover.
Arcutis Biotherapeutics currently holds about 282.17 M in cash with (247.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.47.
Check Arcutis Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Arcutis Biotherapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcutis Biotherapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcutis Biotherapeutics. Please pay attention to any change in the institutional holdings of Arcutis Biotherapeutics as this could imply that something significant has changed or is about to change at the company.
Check Arcutis Ownership Details
Arcutis Biotherapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arcutis Biotherapeutics market risk premium is the additional return an investor will receive from holding Arcutis Biotherapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1547 | |||
| Jensen Alpha | 0.7409 | |||
| Total Risk Alpha | 0.6662 | |||
| Sortino Ratio | 0.1722 |
Arcutis Stock Against Markets
Arcutis Biotherapeutics Corporate Management
| JD Esq | General VP | Profile | |
| Patricia Turney | VP Operations | Profile | |
| Todd Edwards | Executive Officer | Profile | |
| Eric McIntyre | Head Relations | Profile | |
| Ayisha Jeter | Head Access | Profile | |
| David Osborne | Chief Officer | Profile | |
| Bethany Dudek | Chief Officer | Profile |
Already Invested in Arcutis Biotherapeutics?
The danger of trading Arcutis Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcutis Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcutis Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcutis Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.